# Supplementary Figure 11



**A** Imaging flow cytometry of PDAC patient agrin+ EVs coupled to beads

**B** Non-Folfirinox-based regimens

**C**

**D**

**E**

**Supplementary Figure 11 (related to Figure 8). Combination of Agrin and YAP levels correlates with worse prognosis in PDAC. (A)** Representative FACS and imaging flow cytometry analysis of agrin-positive EVs coupled to beads in the serum of PDAC patients. **(B)** Pre- and post-chemotherapy analysis of the percentage of circulating agrin-positive EVs coupled to beads in the serum of PDAC patients treated with non-folfirinox-based regimens (n=11, paired t-test). **(C)** Kaplan-Meier curve of disease-free survival of PDAC patients showing high expression levels of agrin (RNA) and YAP (protein) (purple) or low levels of agrin and YAP (blue) (TCGA cohort of PDAC patients n=48, Log-Rank test *$p$=0.028). **(D)** Kaplan-Meier curve of the disease-free survival of PDAC patients showing high expression of agrin and low phosphoS127 YAP (yellow) and vice-versa (green) (TCGA cohort of PDAC patients n=40, Log-Rank test *$p$=0.02). **(E)** Kaplan-Meier curve of the disease-free survival of PDAC patients showing high expression of phosphoS127 YAP (black) or low (grey) (TCGA cohort of PDAC patients n=89, Log-Rank test $p$=0.1).